Japan Cardiac Surgery Instruments Market - Top Companies and Manufacturers

Introduction
1. Study Objective
2. Scope of the report
3. Market Taxonomy
Study Assumptions and Abbreviations
1. Research Methodology
2. Secondary Research
3. Primary Research
4. SPSS Approach
5. Data Triangulation
Executive Summary
Japan Industry Overview
1. Market Overview
2. Industry Supply Chain Analysis
3. DROT
4. Regulatory Framework Governing the Handling of NH₄HCO₃
5. Competitive Landscape
  1. Terumo Corporation
  2. Fukuda
  3. LivaNova
  4. B. Braun
  5. Medline Industries
  6. KLS Martin
  7. STILLE
  8. Nipro Corporation
Japan Outlook and Projections
1. Japan Overview
  1. Market Value (USD Million), Volume (Thousand Tons), Current and Future Projections, 2025-2036
  2. Increment $ Opportunity Assessment, 2025-2036
  3. Year-on-Year Growth Forecast (%)
2. Segmentation (USD Million), 2025-2036, By
  1. Product Type, Value (USD Million), Volume (Thousand Tons)
    1. Forceps
    2. Clamps
    3. Scalpels
    4. Scissors
    5. Needle Holders
    6. Others
  2. Application, Value (USD Million), Volume (Thousand Tons)
    1. Coronary Artery Bypass Graft
    2. Heart Valve Surgery
    3. Pediatric Cardiac Surgery
    4. Heart Transplant
    5. Others
  3. End user, Value (USD Million), Volume (Thousand Tons)
    1. Hospitals and Cardiac Centers/Clinics
    2. Ambulatory Surgical Centers
About Research Nester
1. Our Global Clientele
2. We Serve Clients Across World

Companies Dominating the Japan Cardiac Surgery Instruments Landscape

The market for cardiac surgery instruments in Japan is highly competitive, and the key players are increasingly focusing on product innovation. The key players in the japan cardiac surgery instruments market are Terumo Corporation, Nipro, and Fukuda because they innovate new surgical devices for treating cardiovascular diseases. Other firms such as LivaNova and Medline Industries are dedicated to developing surgical solutions that help improve the efficiency and accuracy of cardiac surgeries.

In April 2024, Toyoda Gosei revealed new developments in its biopolymer-based cardiac implants to enhance heart valve replacement and restoration. This development is in line with the current trend of the japan cardiac surgery instruments market, which has moved towards bioengineered surgical solutions, which is in line with Japan’s long-term vision for its healthcare industry. Through innovation and the introduction of new products, market leaders are enhancing their market standings, thus guaranteeing continuous growth in the market.

Here are some leading companies in the Japan cardiac surgery instruments market:

Terumo Corporation
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Fukuda
LivaNova
B. Braun
Medline Industries
KLS Martin
STILLE
Nipro Corporation

Browse Key Market Insights with Data Illustration:

Japan Cardiac Surgery Instruments Market Size | Growth Analysis 2036

In the News

In June 2024, Boston Scientific received regulatory approval in Japan for its FARAPULSE Pulsed Field Ablation (PFA) system, designed to treat patients with atrial fibrillation. The technology offers a minimally invasive option that selectively targets cardiac tissue while minimizing damage to surrounding areas. This approval enhances Boston Scientific’s electrophysiology portfolio and strengthens its presence in Japan’s growing cardiac surgery market.
In May 2024, Toyoda Gosei announced the development of a novel medical valve for use in artificial heart systems, contributing to Japan's advancements in mechanical circulatory support devices. The valve, designed for durability and efficiency, supports prolonged cardiac function in patients with severe heart conditions. Toyoda Gosei’s expansion into cardiac surgery instruments reflects diversification efforts to meet growing demands in Japan’s healthcare market.
In April 2024, Terumo Corporation launched the CAPIOX NX19 oxygenator in Japan, aimed at enhancing extracorporeal circulation during cardiac surgery. The NX19 features improved gas exchange efficiency and advanced coating technology to reduce blood damage, aligning with the increasing demand for more sophisticated cardiopulmonary bypass systems. This product expansion reflects Terumo’s commitment to advancing surgical outcomes and broadening its footprint in Japan’s cardiac surgery sector.

Frequently Asked Questions (FAQ)

In 2024, the industry size of Japan Cardiac Surgery Instruments was USD 141.3 million.

Japan cardiac surgery instruments market size was USD 141.3 million in 2024 and is expected to reach USD 357.1 million by the end of 2036, expanding at a CAGR of 8.0% during the forecast period, i.e., 2025-2036. In 2025, the industry size of Japan Cardiac Surgery Instruments will be valued at USD 151.7 million.

Key players in the market are Terumo Corporation, Fukuda, LivaNova, B. Braun, Medline Industries, KLS Martin, STILLE, Nipro Corporation.

The forceps segment is anticipated to lead Japan cardiac surgery instruments market during the forecast period.

Tokyo is likely to offer expansion prospects to the companies in Japan cardiac surgery instruments market during the forecast period.

Japan Cardiac Surgery Instruments Market - Top Companies and Manufacturers

Companies Dominating the Japan Cardiac Surgery Instruments Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is japan cardiac surgery instruments industry?

What is the outlook for Japan cardiac surgery instruments market?

Who are the major players dominating Japan cardiac surgery instruments landscape?

Which segment will capture the significant market share for Japan Cardiac Surgery Instruments by 2036?

Which city will provide more opportunities for players in Japan Cardiac Surgery Instruments business in the coming years?